Shares of Petmed Express Inc (NASDAQ:PETS) have been assigned a consensus rating of “Hold” from the eight brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $42.80.

Several research firms have weighed in on PETS. BidaskClub raised Petmed Express from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 9th. ValuEngine upgraded Petmed Express from a “hold” rating to a “buy” rating in a research note on Wednesday, February 7th. Finally, Northcoast Research set a $58.00 price target on Petmed Express and gave the company a “buy” rating in a research note on Wednesday, January 3rd.

How to Become a New Pot Stock Millionaire

Petmed Express (PETS) opened at $46.75 on Monday. The company has a market capitalization of $963.10, a price-to-earnings ratio of 27.66, a price-to-earnings-growth ratio of 2.64 and a beta of 0.93. Petmed Express has a one year low of $19.21 and a one year high of $57.80.

Petmed Express (NASDAQ:PETS) last posted its quarterly earnings data on Monday, January 22nd. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.11. The company had revenue of $60.10 million for the quarter, compared to analyst estimates of $56.76 million. Petmed Express had a return on equity of 34.04% and a net margin of 12.84%. The business’s revenue was up 13.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.24 earnings per share. equities research analysts anticipate that Petmed Express will post 1.77 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, February 16th. Stockholders of record on Monday, February 5th were given a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 2.14%. This is a boost from Petmed Express’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend was Friday, February 2nd. Petmed Express’s dividend payout ratio (DPR) is presently 59.17%.

In other Petmed Express news, CEO Menderes Akdag sold 30,000 shares of the firm’s stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $51.00, for a total transaction of $1,530,000.00. Following the transaction, the chief executive officer now owns 490,000 shares in the company, valued at approximately $24,990,000. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Ronald J. Korn sold 5,000 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $48.38, for a total value of $241,900.00. Following the transaction, the director now owns 68,833 shares in the company, valued at approximately $3,330,140.54. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 65,000 shares of company stock valued at $3,229,500. Insiders own 4.00% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Elkfork Partners LLC bought a new position in shares of Petmed Express in the 4th quarter valued at $100,000. MetLife Investment Advisors LLC bought a new stake in Petmed Express during the 4th quarter worth $429,000. BB&T Securities LLC bought a new stake in Petmed Express during the 4th quarter worth $254,000. Municipal Employees Retirement System of Michigan grew its position in Petmed Express by 23.5% during the 4th quarter. Municipal Employees Retirement System of Michigan now owns 20,790 shares of the company’s stock worth $945,000 after acquiring an additional 3,960 shares during the last quarter. Finally, LPL Financial LLC bought a new stake in Petmed Express during the 4th quarter worth $238,000. Institutional investors own 91.30% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Petmed Express Inc (PETS) Given Consensus Rating of “Hold” by Brokerages” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.thecerbatgem.com/2018/03/12/petmed-express-inc-pets-given-consensus-rating-of-hold-by-brokerages.html.

Petmed Express Company Profile

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Analyst Recommendations for Petmed Express (NASDAQ:PETS)

Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.